Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors

Trial Profile

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 21 Sep 2016 Status changed from recruiting to completed.
    • 26 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 05 Aug 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jun 2015 to 1 Sep 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top